Latest Biotech News

Page 1 of 27
Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.
Ada Torres
Ada Torres
23 Dec 2025
TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.
Ada Torres
Ada Torres
22 Dec 2025
Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.
Ada Torres
Ada Torres
22 Dec 2025
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.
Ada Torres
Ada Torres
22 Dec 2025
Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.
Ada Torres
Ada Torres
16 Dec 2025
Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.
Ada Torres
Ada Torres
16 Dec 2025
Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.
Ada Torres
Ada Torres
15 Dec 2025
Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.
Ada Torres
Ada Torres
15 Dec 2025
InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.
Ada Torres
Ada Torres
10 Dec 2025
Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.
Ada Torres
Ada Torres
10 Dec 2025
CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.
Victor Sage
Victor Sage
8 Dec 2025
Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.
Ada Torres
Ada Torres
4 Dec 2025